Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments
Launched by CENTRE HOSPITALIER METROPOLE SAVOIE · Feb 15, 2024
Trial Information
Current as of September 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a condition called sarcopenia, which means having low muscle mass and strength, might affect the side effects that patients experience during their first round of cancer treatment. Researchers want to find out if having sarcopenia can help predict whether someone will have more severe side effects from treatments like chemotherapy. To do this, they will look at the body composition and muscle performance of participants through specific tests.
To be eligible for this trial, participants need to be at least 18 years old and have a confirmed diagnosis of a solid tumor that requires systemic treatment. They should also be able to provide consent to join the study and be part of a social security system. Unfortunately, those with a recent history of certain cancers, those not needing systemic treatment, pregnant women, and a few others will not be able to participate. Participants can expect to undergo tests that measure their muscle strength and body composition, which will help researchers understand the relationship between sarcopenia and treatment side effects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 years old
- • Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment.
- • CT/PET performed within 45 days before initiation of systemic treatment.
- • Patient able to sign informed consent for participation in the study
- • Patient affiliated to a social security system
- Exclusion Criteria:
- • History of cancer in the five years preceding inclusion other than localized skin or cervical cancers.
- • Patient with cancer not requiring systemic treatment.
- • Pregnant women.
- • Patient with a pace maker or defibrillator
- • Patient deprived of liberty or benefiting from a legal protection measure
About Centre Hospitalier Metropole Savoie
Centre Hospitalier Métropole Savoie is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Located in the Auvergne-Rhône-Alpes region of France, the center collaborates with a multidisciplinary team of healthcare professionals and researchers to conduct rigorous clinical studies across various therapeutic areas. With a commitment to ethical standards and patient safety, the Centre Hospitalier Métropole Savoie aims to contribute to the development of new treatments and enhance clinical practices, ultimately benefiting the broader medical community and the patients they serve.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chambéry, , France
Patients applied
Trial Officials
Aurelie FILLON
Principal Investigator
Centre Hospitalier Metropole Savoie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported